Travere Therapeutics, Inc. — Earnings Quality Grade F
TVTX · Healthcare
Major red flags
Screening Summary
管理层信号
Financial Trends
Revenue & Net Income ($B)
Margins (%)
18-Point Screening
Revenue Quality
DSO surged by 17 days (42 → 60)
AR growth 195.5% exceeds revenue growth 110.5%
Revenue 110.5%, CFFO 115.9%. Cash follows revenue
Expense Quality
Inventory -5.2% vs COGS 33.5%. Normal
CapEx growth -42.5% vs revenue 110.5%. Normal
SG&A/Gross Profit = 70.2%, exceeds 70%
Gross margin 97.9%, change +1.2pp. Stable
Cash Flow Quality
CFFO/NI = -1.48. Below 1.0
FCF is negative ($-0.0B)
Accruals ratio = -10.5%. Low accruals
Cash $0.3B covers 98% of debt $0.3B
Balance Sheet Health
Goodwill+Intangibles $0.1B = 99% of equity. Over 50%
Debt/EBITDA = 14.8x (>4x). Interest coverage = -5.8x (<2x). Financial stress
Other assets -27.2% vs revenue 110.5%. Normal
No write-off data
Acquisition Risk
FCF after acquisitions negative for 3 years
Goodwill+Intangibles change 9% YoY. Normal
Manipulation Score
M-Score = -1.56 (> -1.78). LIKELY MANIPULATOR
Beneish M-Score
Altman Z-Score
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25